A study of CCX-140 in patients with focal segmental glomerulosclerosis (FSGS)
Phase of Trial: Phase III
Latest Information Update: 08 Aug 2017
At a glance
- Drugs CCX 140 (Primary)
- Indications Focal segmental glomerulosclerosis
- Focus Registrational; Therapeutic Use
- Sponsors ChemoCentryx
- 08 Aug 2017 According to a ChemoCentryx media release, the company expects to initiate this train in later 2017.
- 20 Jan 2017 New trial record
- 09 Jan 2017 According to a ChemoCentryx media release, the company expects to initiate this study in 2017.